# AnBogen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anbogen-therapeutics

- Industry: Biotechnology
- Headquarters: Taipei, Taiwan - China
- Website: www.anbogen.com
- Total disclosed funding: $13M
- Latest round: Series A (Feb 1, 2024)
- Investors on record: 4

## About

Established in 2019 and based in Taipei, China, AnBogen Therapeutics, Inc. operates as a drug development company that develops oncology drugs. The company was founded by its CEO, Tsu-An Hsu, Chuan Shih, and Hsing-Pang Hsieh. In February 2024, AnBogen Therapeutics raised USD 12.5 million in Series A funding led by China Development Industrial Bank, TaiAn Technologies Corporation, Maxpro Ventures, and the National Development Fund. In July 2024, the firm raised USD 7.3 million in series A+ funding. 

AnBogen Therapeutics, Inc. offers a clinical-stage biotechnology platform, which is a cancer drug development platform that develops medicines, mainly precision oncology drugs, for cancer patients. The company develops drugs with the help of its drug candidates: ABT-101, an oral tyrosine kinase inhibitor (TKI) for non-small cell lung cancer; ABT-202, a second-generation KRAS inhibitor; and ABT-301, a small-molecule histone deacetylase inhibitor (HDACi) for treating various solid tumors.

The company’s revenue is generated by providing oncology treatment drugs.

The company will use the series A+ funding to broaden and improve the business's product research.

## Funding rounds

- Series A, Feb 1, 2024, $13M — CDIB Capital Group, TaiAn Technologies Corporation, National Development Fund, Maxpro Venture

## Investors

- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series A
- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series A
- National Development Fund (https://capitalatlas.ai/funds/national-development-fund) — Series A
- Maxpro Venture (https://capitalatlas.ai/funds/maxpro-venture) — Series A